CryptoFundManager

SESN Sesen Bio Selloff | Buy the dip???

Long
NASDAQ:SESN   Sesen Bio, Inc
SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support.

The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls ( CMC ) issues pertaining to a recent pre-approval inspection and product quality. (businesswire.com)

And they don`t have only one product in their pipeline.

Sesen Bio focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio , Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. (marketbeat.com)

On 8/11/2021 BlackRock Inc . reported 10,657,812 for a total of $49.24M +264.7% increase and an ownership in SESN of 6.150%
On 8/13/2021 Vanguard Group Inc. reported 8,503,982 for a total of $39.29M +18.2% increase and an ownership in SESN 4.339%

My price target is between 2.7 to 3.2usd.

I look forward to read your opinion






Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.